COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details) $ / shares in Units, Unit in Millions						3 Months Ended				6 Months Ended				12 Months Ended
		Aug. 04, 2022 $ / shares	Apr. 05, 2022 $ / shares	Mar. 19, 2021 Claim	Jan. 03, 2020 USD ($) shares	Jun. 30, 2022 USD ($) KeyEmployee		Jun. 30, 2021 USD ($)		Jun. 30, 2022 USD ($) Unit Applicants KeyEmployee Claim		Jun. 30, 2021 USD ($)		Dec. 31, 2020 Lawsuit	Dec. 31, 2021 USD ($)
Concentrations [Abstract]
Net product revenue						$ 9,161,430		$ 6,462,110		$ 27,978,041		$ 15,186,469
Accounts Receivable						4,255,944				4,255,944					$ 11,441,107
Purchase obligations						$ 500,000				$ 500,000
Minimum volume commitment | Unit										10
Employment Contracts [Abstract]
Number of key employees with whom Company has employment contracts | KeyEmployee						3				3
Aggregate annual salaries of employment contracts										$ 1,178,000
Contract one, expiration date										Dec. 31, 2022
Contract two expiration date										Dec. 31, 2024
Future minimum salary commitments [Abstract]
2022						$ 589,000				$ 589,000
2023						383,000				383,000
2024						383,000				$ 383,000
Benefit Plan [Abstract]
Percentage of employer's matching contribution										40.00%
Expenses related to matching contribution						37,778		29,933		$ 104,913		65,388
Components of Lease Expense [Abstract]
Operating lease expense						372,232		402,329		775,617		810,795
Finance lease cost [Abstract]
Amortization of right-of-use assets						17,850		17,038		35,429		32,796
Interest on lease liabilities						4,480		5,368		9,166		10,312
Total finance lease expense						22,330		22,406		44,595		43,108
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Operating cash flows for operating leases						361,325		348,317		722,204		696,188
Operating cash flows for finance leases						4,480		5,368		9,166		10,312
Financing cash flows for finance leases						17,491		15,538		34,421		29,820
Right-of-use assets obtained in exchange for lease obligations [Abstract]
Finance leases						0		25,609		16,234		25,609
Operating leases						717,956		694,668		717,956		694,668
Finance Leases [Abstract]
Finance lease right of use asset						356,997		340,762		356,997		340,762
Accumulated depreciation						(184,321)		(114,815)		(184,321)		(114,815)
Finance lease right of use asset, net						$ 172,676		$ 225,947		$ 172,676		$ 225,947			191,870
Weighted Average Remaining Lease Term [Abstract]
Operating leases						7 years		7 years 10 months 24 days		7 years		7 years 10 months 24 days
Finance leases						2 years 4 months 24 days		3 years 4 months 24 days		2 years 4 months 24 days		3 years 4 months 24 days
Weighted Average Discount Rate [Abstract]
Operating leases						8.75%		8.73%		8.75%		8.73%
Finance leases						9.05%		8.43%		9.05%		8.43%
Maturities of Operating Lease Liabilities [Abstract]
2022						$ 731,574		$ 708,344		$ 731,574		$ 708,344
2023						1,428,820		1,447,249		1,428,820		1,447,249
2024						1,220,150		1,221,017		1,220,150		1,221,017
2025						1,049,441		1,018,875		1,049,441		1,018,875
2026						1,080,925		1,049,442		1,080,925		1,049,442
Thereafter						3,643,521		4,724,446		3,643,521		4,724,446
Total lease payments						9,154,431		10,169,373		9,154,431		10,169,373
Less: imputed interest						2,371,852		2,909,688		2,371,852		2,909,688
Total						6,782,579		7,259,685		6,782,579		7,259,685
Maturities of Finance Lease Liabilities [Abstract]
2022						43,942		41,812		43,942		41,812
2023						87,884		83,624		87,884		83,624
2024						60,116		83,624		60,116		83,624
2025						16,731		55,856		16,731		55,856
2026						5,940		12,471		5,940		12,471
Thereafter						355		1,680		355		1,680
Total lease payments						214,968		279,067		214,968		279,067
Less: imputed interest						25,301		39,166		25,301		39,166
Total						$ 189,667		239,901		$ 189,667		239,901
Stockholder Litigation [Abstract]
Number of class action lawsuits | Lawsuit														4
Number of motions for appointment as lead plaintiff | Applicants										8
Number of motions abandoned | Applicants										2
Number of remaining motions for appointment as lead plaintiff | Applicants										2
Number of motions filed by special situations funds | Applicants										1
Number of motions filed by municipal employees retirement system | Applicants										1
Period within which lead plaintiffs can replead their claims						14 days
Notice period to terminate the stipulation										14 days
Pendency period of stay										1 year
Employee Litigation [Abstract]
Number of filed complaints | Claim				15
Exercise price of stock options					$ 943,126
Vested shares exercisable (in shares) | shares					266,666
Term to exercise stock options										30 days
Number of complaint purport to allege claims for breach of each of separate stock option agreements | Claim										10
Loss contingency, asserting damages amount										$ 3,190,198
Loss contingency, asserting damages excess amount										3,000,000
Loss contingency, claims entitlement to recover damages amount										$ 10,000,000
Prejudgment interest rate						9.00%				9.00%
Nasdaq Communications [Abstract]
Minimum bid price requirement, price per share for listing | $ / shares			$ 1.00
Minimum bid price requirement, threshold consecutive business days			30 days
Closing price | $ / shares		$ 1.08
Minimum bid price requirement, threshold consecutive business days to regain compliance		10 days
Customer Concentration Risk [Member] | Customer 1 [Member]
Concentrations [Abstract]
Accounts Receivable						$ 1,534,560				$ 1,534,560						[1]
Customer Concentration Risk [Member] | Customer 2 [Member]
Concentrations [Abstract]
Accounts Receivable						1,066,340				1,066,340					1,433,305
Customer Concentration Risk [Member] | Customer 3 [Member]
Concentrations [Abstract]
Accounts Receivable						996,619				996,619						[1]
Customer Concentration Risk [Member] | Customer4 [Member]
Concentrations [Abstract]
Accounts Receivable						399,420				399,420					7,672,845
Supplier Concentration Risk [Member] | Vendor 1 [Member]
Concentrations [Abstract]
Accounts Payable							[1]				[1]				1,361,383
Supplier Concentration Risk [Member] | Vendor 2 [Member]
Concentrations [Abstract]
Accounts Payable						166,945				166,945					353,097
Supplier Concentration Risk [Member] | Vendor 3 [Member]
Concentrations [Abstract]
Accounts Payable						187,630				$ 187,630
Maximum [Member]
Benefit Plan [Abstract]
Employee contribution subject to employer matching contribution										5.00%
Employer matching contribution										2.00%
Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]
Concentrations [Abstract]
Net product revenue						$ 1,947,390			[1]	$ 3,431,910			[1]
Percentage of product sales						22.00%			[1]	13.00%			[1]
Sales [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]
Concentrations [Abstract]
Net product revenue						$ 1,729,310		$ 1,014,638			[1]	$ 1,151,615
Percentage of product sales						20.00%		26.00%			[1]	15.00%
Sales [Member] | Customer Concentration Risk [Member] | Customer 3 [Member]
Concentrations [Abstract]
Net product revenue						$ 1,633,957			[1]		[1]		[1]
Percentage of product sales						18.00%			[1]		[1]		[1]
Sales [Member] | Customer Concentration Risk [Member] | Customer4 [Member]
Concentrations [Abstract]
Net product revenue							[1]		[1]	$ 12,339,644			[1]
Percentage of product sales							[1]		[1]	45.00%			[1]
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]
Concentrations [Abstract]
Percentage of product sales	[1]
Purchases	[1]
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]
Concentrations [Abstract]
Percentage of product sales							[1]		[1]	15.00%			[1]
Purchases							[1]		[1]	$ 1,589,033			[1]
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 3 [Member]
Concentrations [Abstract]
Percentage of product sales						19.00%			[1]	35.00%			[1]
Purchases						$ 1,317,233			[1]	$ 3,640,838			[1]

[1] In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.